YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Source: FDA

How we engage and involve patients and the public in our regulatory decision-making.

Source: MHRA

This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.

Source: FDA

Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

Source: FDA

The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.

Source: MHRA

Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for nontuberculous mycobacterial lung disease patients.

Source: FDA

The ongoing trial of nerandomilast could significantly impact Boehringer Ingelheim's positioning in the competitive landscape of lung fibrosis treatments. A successful outcome may not only enhance their portfolio but also provide a novel therapeutic option for patients with limited existing treatments. Regulatory context from FDA (Drug Trials Snapshots: YARTEMLEA) supports the near-term read. Assessment grounded in 4 ranked evidence items (3 high-relevance).

Source: Humanexa Insight

The approval of nerandomilast introduces a new competitive player in the pulmonary fibrosis market, which could disrupt existing market dynamics. Pharma strategy teams must evaluate the implications for their portfolios and consider differentiation strategies to maintain market share. Regulatory context from MHRA (Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis) supports the near-term read. Assessment grounded in 6 ranked evidence items (3 high-relevance).

Source: Humanexa Insight

Aurobindo Pharma's receipt of Abbreviated Approval (AP) for Pirfenidone signifies a new competitive entrant in the idiopathic pulmonary fibrosis market. This development necessitates a reassessment of market strategies by existing players to maintain their market share and pricing integrity. Regulatory context from FDA (FDA AP — PIRFENIDONE (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (4 high-relevance).

Source: Humanexa Insight

The establishment of a biorepository for Pulmonary Hypertension could lead to significant advancements in biomarker discovery, enhancing diagnostic and therapeutic strategies. This initiative may reshape competitive dynamics in the PH market, necessitating close observation by pharma companies involved in this therapeutic area. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).

Source: Humanexa Insight

This study highlights the significant role of environmental factors, specifically air pollution, in the severity of cystic fibrosis among Hispanic children. Understanding these influences could reshape clinical strategies and patient education for CF therapies, particularly in addressing health disparities. Regulatory context from FDA (FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (11 high-relevance).

Source: Humanexa Insight

The launch of Zepbound® as the first prescription treatment for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity is a significant development in the pulmonology space. Partnering with a high-profile figure like Shaquille O'Neal enhances brand visibility, potentially driving patient engagement and market share. Regulatory context from MHRA (Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings) supports the near-term read. Assessment grounded in 20 ranked evidence items (20 high-relevance).

Source: Humanexa Insight